Combination therapy with macitentan and phosphodiesterase type-5 inhibitor (PDE5i) in pulmonary arterial hypertension (PAH): real-world data from OPUS and OrPHeUS

被引：0
|
作者：
McLaughlin, V [1 ]
Channick, R. [2 ]
Kim, N. H. [3 ]
Flynn, M. [4 ]
Leroy, S. [5 ]
Wetherill, G. [5 ]
Chin, K. [6 ]
机构：
[1] Univ Michigan, Div Cardiovasc Med, Ann Arbor, MI 48109 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[3] Univ Calif San Diego, San Diego, CA 92103 USA
[4] Actel Pharmaceut US Inc, San Francisco, CA USA
[5] Actel Pharmaceut Ltd, Allschwil, Switzerland
[6] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
来源：
EUROPEAN HEART JOURNAL | 2020年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2297 / 2297
页数：1
相关论文
共 50 条
  • [21] Changes in cMRI parameters following a switch to riociguat from phosphodiesterase type 5 inhibitors (PDE5i) in patients with pulmonary arterial hypertension: a REPLACE substudy
    Rosenkranz, S.
    Benza, R. L.
    Ghofrani, H. A.
    Gruenig, E.
    Hoeper, M. M.
    Peacock, A.
    Simonneau, G.
    Vizza, D.
    Meier, C.
    Vogtlaender, K.
    Vonk-Noordegraaf, A.
    [J]. EUROPEAN HEART JOURNAL, 2021, 42 : 1966 - 1966
  • [22] Real-World Mono-, Double and Triple Combination Treatment Patterns with Macitentan in Patients with Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (PAH-CTD): Evidence from the Combined OPUS/OrPHeUS Dataset
    Lammi, M. R.
    Chin, K.
    Kim, N. H.
    McLaughlin, V. V.
    Zamanian, R.
    Flynn, M.
    Leroy, S.
    Ong, R.
    Wetherill, G.
    Channick, R.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [23] Real-World Mono-, Double and Triple Combination Treatment Patterns with Macitentan in Patients with Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (PAH-CTD): Evidence from the Combined OPUS/OrPHeUS Dataset
    Lammi, Matthew
    Chin, Kelly
    Kim, Nick H.
    McLaughlin, Vallerie
    Zamanian, Roham
    Flynn, Megan
    Leroy, Sandrine
    Ong, Rose
    Wetherill, Graham
    Channick, Richard
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [24] COMORBIDITIES IN PULMONARY ARTERIAL HYPERTENSION (PAH): INSIGHTS FROM THE REAL-WORLD OPSUMIT® USERS (OPUS) REGISTRY
    Rajagopal, Sudarshan
    Channick, Richard
    Chin, Kelly
    Kim, Nick H.
    Flynn, Megan
    Leroy, Sandrine
    Ong, Rose
    Wetherill, Graham
    McLaughlin, Vallerie V.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 2101 - 2101
  • [25] Safety of macitentan for the treatment of pulmonary hypertension: Real-world experience from the OPsumit® USers Registry (OPUS) and OPsumit® Historical USers cohort (OrPHeUS)
    McLaughlin, Vallerie V.
    Channick, Richard
    Kim, Nick H.
    Frantz, Robert P.
    McConnell, John W.
    Melendres-Groves, Lana
    Miller, Chad
    Ravichandran, Ashwin
    Rodriguez-Lopez, Josanna
    Brand, Monika
    Leroy, Sandrine
    Wetherill, Graham
    Chin, Kelly M.
    [J]. PULMONARY CIRCULATION, 2022, 12 (04)
  • [26] Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study
    Kimura, Mai
    Tamura, Yuichi
    Takei, Makoto
    Yamamoto, Tsunehisa
    Ono, Tomohiko
    Fujita, Jun
    Kataoka, Masaharu
    Kuwana, Masataka
    Satoh, Toru
    Fukuda, Keiichi
    [J]. BMC PULMONARY MEDICINE, 2015, 15
  • [27] Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study
    Mai Kimura
    Yuichi Tamura
    Makoto Takei
    Tsunehisa Yamamoto
    Tomohiko Ono
    Jun Fujita
    Masaharu Kataoka
    Masataka Kuwana
    Toru Satoh
    Keiichi Fukuda
    [J]. BMC Pulmonary Medicine, 15
  • [28] Right Ventricular Function and Pulmonary Artery Compliance Improve with Phosphodiesterase type 5A (PDE5A) Inhibitor Therapy in Pulmonary Hypertension
    Aponte, M. M. Patarroyo
    Pritzker, M. R.
    Weir, K.
    Sharma, A.
    Rasmussen, J.
    Thenappan, T.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2014, 33 (04): : S230 - S231
  • [29] TREATMENT PATTERNS IN PULMONARY ARTERIAL HYPERTENSION: CHANGES IN CLINICAL PRACTICE OVER TIME USING REAL-WORLD EVIDENCE FROM THE COMBINED OPUS/ORPHEUS DATA SETS
    Chin, Kelly
    Channick, Richard
    McLaughlin, Vallerie
    Miller, Chad
    Flynn, Megan
    Ong, Rose
    Wetherill, Graham
    Kim, Nick
    [J]. CHEST, 2020, 158 (04) : 2194A - 2196A
  • [30] HEALTHCARE UTILIZATION AND COSTS IN PULMONARY ARTERIAL HYPERTENSION (PAH) PATIENTS TREATED WITH ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS) OR PHOSPHODIESTERASE TYPE 5 INHIBITORS (PDE5IS)
    Hill, J.
    Lickert, C.
    Cole, M.
    McGuiness, K.
    Wade, R. L.
    Drake, W.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A260 - A260
12345